Bioequivalence trials: the regulator-facing spine of generic pathways.
Bioequivalence trials are where pharmacokinetics meets the regulator. The discipline of demonstrating that a generic or alternative formulation is therapeutically interchangeable with the reference. Crossover designs, RSABE for highly variable drugs, special handling for narrow therapeutic index products. Multi-jurisdictional and harmonising on ICH M13A.
What a bioequivalence study looks like.
PK · GMR · crossoverA bioequivalence study produces three regulator-facing artefacts in tandem. The PK profile shows test-vs-reference plasma concentration over time. The GMR forest plot places the geometric-mean ratio + 90% CI for Cmax, AUC0-t, and AUC0-∞ against the 80–125% goalposts. The crossover design grid encodes how subjects flow through Period 1 and Period 2 with washout. Together, they are how regulators read whether two formulations are interchangeable.
The iFeed.bioequivalence reference, in headlines.
2026-05-02 · live80–125%.
90% CI on log-transformed AUC and Cmax. Schuirmann TOST since 1987 · codified by 21 CFR 320 amendment 1992. Universal across FDA, EMA, ANVISA, WHO.
7 anchored.
ICH M13A (Step 4 Jul 2024) · FDA 21 CFR 320 · EMA CPMP/EWP/QWP/1401/98 · ANVISA RDC 742/2022 · WHO TRS 1003 Annex 6 (2017, supersedes TRS 992 Annex 7) · PMDA · CDSCO.
5 patterns.
2×2 crossover · replicate (full / partial) · parallel · multiple-dose · biowaiver (BCS Class I / III). RSABE for HV drugs.
1 standing.
FDA-EMA disagreement on highly variable drug scaling persists post-M13A. FDA permits reference-scaled BE on both AUC and Cmax. EMA permits widening only of Cmax to 0.6984–1.4319 with justified clinical rationale; AUC stays 80.00–125.00% regardless of variability. Sponsors filing in both regions design around it.
This domain connects to three.
Bioequivalence doesn't sit aloneBioequivalence runs on the bioanalytical spine and shares ICH GCP discipline with clinical trials. Governance gates everything. Click a node to open that space.
Nine chapters · open any.
Each chapter is its own page · secondary nav abovePillars: cross-regulator BE comparison.
80–125% TOST acceptance bound. Study designs (2×2, replicate, parallel). Reference-product handling. Biowaivers (BCS Class I & III). RSABE for HV drugs. ICH M13A · FDA · EMA · ANVISA · WHO · CDSCO · PMDA cross-walk.
Open chapter →
BE substrate.
CRO oversight model. Healthy-volunteer regimes (registries, screening, washout). Clinical-pharmacology unit infrastructure. Sponsor-CRO contracting. Sample collection bridge to bioanalytical. Crossover-period mechanics.
Open chapter →
History & evolution.
Lindenbaum 1971 NEJM digoxin paper. Hatch-Waxman 1984. Schuirmann TOST 1987. 1992 21 CFR 320 amendment. EMA 2010 Guideline. ICH M13A 2024. From observation to harmonised global text.
Open chapter →
Current state: 2026.
ICH M13A in implementation across regions. FDA accepts on transition pathway through 2026. EMA published implementation. PMDA aligned April 2025. ANVISA RDC 742/2022 effective. RSABE divergence still active.
Open chapter →
Future scope: 2026-2035.
ICH M13B/C in development. Modelling-and-simulation (M&S) gradual acceptance for biowaivers. Virtual BE pilots. AI-augmented PK derivation. Scaling-method convergence question post-M13A.
Open chapter →
AI in bioequivalence.
PK derivation model assistance. Outlier-detection in BE datasets. Volunteer-screening risk stratification. Virtual BE simulations as supportive evidence. PCCP framework relevance for adaptive AI in BE pipelines.
Open chapter →
Flow of BE trials.
Protocol design → reference-product sourcing → volunteer recruitment → clinical conduct (Period 1, washout, Period 2) → bioanalytical → PK derivation → statistical analysis → CSR → submission. Sequential and gated.
Open chapter →
People: use cases, players, stakeholders.
Eight regulatory triggers (ANDA, biosimilar bridging, EU/Brazil generic registration, post-approval changes, biowaivers). Five player categories: BE-specialist CROs, generic-drug pharma, regulators, tech vendors, standards bodies. Stakeholder map.
Open chapter →
Notes: bioequivalence writing.
The feed of writing relevant to bioequivalence practice. ICH M13A, RSABE for highly variable drugs, the FDA-EMA divergence, biowaivers. Filtered from the global notes archive.
Open chapter →
Study designs.
Design typesDesign choice is dictated by the molecule's PK profile, variability, and intended population. The wrong design is unrescuable; the right design produces inspection-ready data on first read.
2×2 crossover.
The standard for moderately variable drugs. Two periods, two sequences, randomised. Subjects act as their own control. Default for most generic submissions.
Replicate (3-period) for RSABE.
For highly variable drugs (CV ≥ 30%). Replicate of reference, scaled-average bioequivalence. Wider acceptance window when within-subject variability is high.
4-period full replicate.
Both test and reference replicated. Estimates within-subject variability for both formulations. Used for NTI and complex generics.
Parallel group.
For drugs with very long half-lives where crossover is impractical. Larger sample size requirement; specific statistical considerations.
Steady-state multi-dose.
For modified-release products and certain drug classes where single-dose PK is uninformative. Trough sampling, steady-state confirmation.
Fed · fasting.
Most BE programmes require both. Fed-state design follows specific high-fat meal protocols per FDA / EMA. Critical for MR formulations.
Acceptance criteria.
The regulator's barThe geometric mean ratio of test/reference falls within 80%–125% at the 90% confidence interval.
For Cmax and AUC. Tightened for narrow therapeutic index drugs (e.g., 90.00–111.11%). Widened for highly variable drugs via RSABE up to 69.84–143.19% at maximum scaling. The window is narrow, the calculation is exact, the regulator does not negotiate.
Regulatory regimes.
BE-specific guidance · multi-jurisdictionalPK metrics.
What the study measuresCmax.
Maximum observed concentration. The peak. Sensitive to absorption rate. Critical for IR formulations.
AUC0–t.
Area under curve to last measurable concentration. Total exposure proxy. Primary BE endpoint.
AUC0–∞.
Extrapolated to infinity. Used when AUC∞ / AUC∞ ratio is reasonable. Secondary endpoint typically.
Tmax.
Time to Cmax. Reported descriptively. Sometimes part of acceptance for specific drug classes.
t½.
Apparent terminal half-life. Confirms washout adequacy in crossover. Reported descriptively.
λz.
Terminal elimination rate constant. The slope used to compute t½ and AUC extrapolation.
Cmin.
Steady-state trough. For MR products and steady-state designs. Confirmation of drug accumulation.
Pf%.
Peak-to-trough fluctuation at steady state. Demonstrates equivalent release profile across formulations.
The bioequivalence pillars · cross-regulator comparison.
5 regulators · 9 BE pillarsNine pillars define the operational shape of a defensible BE programme — from study design through statistical engine. Below: a quick-reference grid · then a colour-coded drilldown comparing ICH M13A · FDA · EMA · WHO · ANVISA on each. Highly variable drug scaling (★) is where FDA-EMA divergence runs deepest; reference product sourcing (★) is where ANVISA stands alone.
Quick reference · the nine BE parameters.
Study design.
2×2 crossover default; 3-period replicate for RSABE; 4-period full replicate for NTI; parallel for long t½. Choice is dictated by within-subject variability and intended population.
AUC & Cmax acceptance.
80.00–125.00% · 90% confidence interval · log-transformed AUC and Cmax. Universal across FDA, EMA, ANVISA, WHO. The single most-harmonised pillar in BE.
Highly variable drug scaling.★
RSABR / RSABE for CV ≥ 30%. FDA scales AUC + Cmax (up to 69.84–143.19%); EMA Cmax-only, AUC must hold standard 80–125%. ANVISA EMA-aligned. The deepest operational divergence.
Narrow Therapeutic Index (NTI).
90.00–111.11% bound · full replicate design. NTI lists divergent: FDA longest, EMA shortest, ANVISA most explicitly codified (RDC 742/2022). Reverify per jurisdiction.
BCS biowaivers.
ICH M9 (Step 4 reached 20 November 2019) framework: Class I universally accepted; Class III post-M9 accepted (excipient stricter). Class II/IV not eligible. The pivotal convergence event since 80–125%.
Reference product sourcing.★
FDA: US RLD only. EMA: EU-sourced (bridging for non-EU). ANVISA: strictly locally registered Brazilian innovator (changed 2022, non-negotiable). WHO: flexible to source-country.
Dissolution f2.
Comparative dissolution profile, similarity factor f2 ≥ 50. Required for BCS biowaiver justification, post-approval variation, and as supporting data in BE submissions. Method specifics still diverge.
Biosimilar PK.
Same TOST machinery (80–125%) but totality-of-evidence: analytical → PK → comparative efficacy · immunogenicity in parallel. FDA 351(k) · EMA biosimilar guideline · ANVISA RDC 55/2010. Interchangeability designation diverges.
Statistical engine.
Schuirmann TOST (1987) · log-transformation · geometric mean ratio · 90% CI · point estimate constraint. Global default since 1992 21 CFR 320 amendment. Cited in every subsequent BE guidance.
Cross-regulator comparison · ICH M13A · FDA · EMA · WHO · ANVISA.
/ 5.1 Study design.2×2 crossover · 3-way replicate · 4-way full replicate · parallel. +
/ 5.2 AUC & Cmax acceptance.80.00–125.00% · 90% CI log-transformed · the universal envelope. +
/ 5.3 Highly variable drug scaling.★RSABR / RSABE · FDA AUC + Cmax vs EMA Cmax-only · the deepest divergence. +
/ 5.4 Narrow Therapeutic Index (NTI).90.00–111.11% bound · full replicate · lists divergent. +
/ 5.5 BCS biowaivers.ICH M9 (2019) · Class I + III post-M9 · the convergence event. +
/ 5.6 Reference product sourcing.★RLD · EU-sourced · ANVISA Brazilian-only · the non-negotiable. +
/ 5.7 Dissolution f2.Comparative dissolution profile · similarity factor ≥ 50. +
/ 5.8 Biosimilar PK.Totality of evidence · 351(k) / EMA biosimilar / RDC 55/2010. +
/ 5.9 Statistical engine.Schuirmann TOST · log-transformation · point estimate. +
History: how BE became a regulated discipline.
1971 → 2024Bioequivalence regulation is a chain of failures — each guideline a scar from a specific data integrity rupture, formulation disaster, or scientific paper that reframed the question. The timeline is short and the citations recur in every modern guidance.
Evolution: six eras in fifty years.
Decade arcs · pre-statutory → complex genericThe discipline moves in distinct epochs: each one absorbs the last decade's failure into the next decade's framework. The current era, complex-generic and model-informed, is still being written.
Pre-statutory era.
Lindenbaum identified the problem; FDA internally convened task forces; industry adapted ad hoc to the residue-analysis template. No statute, no acceptance criteria, no inspection regime.
Foundational statutory era.
21 CFR 320 established (1977); Hatch-Waxman created the ANDA pathway (1984). OGD backlog grew; no enforcement mechanism for data integrity. The framework existed; the inspection muscle did not.
Scandal-driven tightening.
The 1989 generic scandal forced 1992 codification of 80–125% TOST, dissolution f2, manufacturing pre-approval inspection, debarment authority. Inspection-driven compliance culture formed.
Highly variable drug & widening.
RSABE framework emerged product-by-product (FDA) versus framework-level (EMA Cmax-only). Divergence between regulators widened; sponsors developed dual-design strategies for parallel submissions.
Biowaiver harmonisation.
WHO TRS 992 set the LMIC template; ICH M9 converged Class I/III acceptance; ANVISA RDC 742/2022 aligned the Brazilian rule. Post-M9 biowaiver scope converged, though operational divergence persists in dissolution method specifics and excipient strictness.
Complex generic & model-informed.
Long-acting injectables, peptides, drug-device combinations force new design paradigms. PBPK / MIDD enters as supportive evidence (FDA 2024) and is projected to enter as primary evidence in the 2030s for selected complex generics.
Current state · 2026.
Live now · in transitionThe 2026 stack is roughly 90% converged on ICH M9 biowaiver scope and the 80–125% bound, with persistent operational divergence in HV drug scaling, NTI lists, and reference product sourcing. What is live, what is moving:
Standard BE bound universal.
80.00–125.00% (90% CI, log-transformed AUC + Cmax) across FDA, EMA, ANVISA, WHO. Schuirmann TOST is the global default statistical method.
HV drug scaling divergence.
FDA: RSABE on AUC + Cmax (up to 69.84–143.19%). EMA: Cmax only, AUC standard 80–125%. ANVISA: EMA-aligned. A US-designed RSABE study must still meet EMA's AUC standard at EU filing.
NTI drug lists divergent.
FDA list longest (warfarin, digoxin, levothyroxine, lithium, theophylline, phenytoin, carbamazepine, cyclosporine, tacrolimus, sirolimus). EMA shortest. ANVISA most explicitly codified (RDC 742/2022). Sponsors must reverify per jurisdiction.
BCS biowaiver convergence.
Post-M9: Class I universally accepted (very rapid dissolution ≥85% in 15 min); Class III accepted with stricter excipient and dissolution criteria. Class II/IV not eligible universally.
Reference product sourcing.
FDA: US RLD, foreign-sourced generally not accepted. EMA: EU-sourced with bridging for non-EU. ANVISA: strictly locally registered Brazilian innovator (changed 2022, non-negotiable). WHO PQ: flexible to source-country.
Biosimilar PK BE distinct.
Same TOST machinery (80–125%) but a totality-of-evidence framework: analytical similarity → PK similarity → comparative efficacy. Immunogenicity (ADA assays) in parallel. Distinct rules in FDA 351(k), EMA biosimilar guideline, ANVISA RDC 55/2010.
Biosimilar interchangeability.
FDA: formal "interchangeable" designation under BPCI Act 2009 (requires switching studies). EMA: no federal designation, member states decide. ANVISA: no formal designation (2026).
ANVISA Rules 2024 operational.
Healthy-volunteer registry mandatory (prevents professional-volunteer cross-contamination); genotoxic impurity record for BE clinical batch mandatory (stricter than FDA/EMA); updated NTI list; Brazilian reference product non-negotiable.
Virtual BE / PBPK trajectory.
FDA 2024 MIDD guidance permits PBPK as supportive for biowaivers, food-effect waiver, dose-proportionality. Full primary-evidence acceptance for selected complex generics projected 2030–2035. EMA 2025 reflection paper cautious.
Global 2026 stack.
Design AUC to standard 80–125% (captures all regulators); scale Cmax under EMA/ANVISA logic (covers FDA as subset); source reference product carefully per jurisdiction; plan ANVISA volunteer registry compliance; document genotoxic impurity for BE clinical batch.
Future scope · 2026–2035.
Projections · confidence calibrated to public signalsEach projection is calibrated against working-group charters, draft documents, inspection patterns and conference outputs. Absence of signal means LOW confidence by definition.
Virtual BE as primary evidence.
Selected complex generics by 2030–2035. Realistic 2026–2030: PBPK supportive for BCS biowaivers, food-effect waivers, dose proportionality. 2030–2035: PBPK + reduced in vivo confirmatory hybrid for technical-impossibility cases.
Long-acting injectable BE frameworks.
By 2028–2030. Risperidone microspheres, paliperidone palmitate, naltrexone depot, GLP-1 LAI generics entering 2026+. FDA PSGs expected 2028; EMA reflection 2027–2029. Steady-state designs and IVIVC release-rate surrogates replacing single-dose crossover.
Complex generic frameworks.
Peptides, suspensions, drug-device. FDA glatiramer acetate (2015) set peptide precedent; liraglutide / semaglutide post-patent pressure drives peptide guidance attempts 2027–2030. ICH-level peptide guidance attempt expected with partial convergence only.
Drug-device BE bridge.
Device interchangeability becomes a regulatory question (patient hand-feel of generic inhaler). FDA orally-inhaled guidance under continuing revision. EU MDR Article 117 notified-body bottleneck easing but still ~12-month review vs. 45-day medicinal-product timeline.
Biosimilar interchangeability.
Convergence by 2030. FDA expanding interchangeability grants; EMA likely to publish federal framework 2027–2028 (member-state pushback expected); ANVISA possible introduction 2028–2030. Realistic: totality-of-evidence without mandatory switching for established biosimilars.
ANVISA-ICH biowaiver operationalisation.
2026–2030. 50–100 case-law decisions expected; ANVISA may publish biowaiver-specific operational guidance ~2028. Persistent Brazilian divergences: locally registered reference, volunteer registry, genotoxic impurity records.
HRMS bioanalytical baseline.
By 2028. Orbitrap, Q-TOF, FT-ICR mature. ICH M10 amendment / companion guidance expected 2028–2030. Mass-accuracy criteria (≤5 ppm) and isotope-pattern confirmation standards setting.
Microsampling standard.
DBS, VAMS by 2030. Currently case-by-case under ICH M10. Population studies, paediatrics and decentralised trials driving acceptance.
Genomic-stratified BE.
2030+. Metabolizer-specific BE designs for CYP polymorphism populations; technically feasible but politically and payer-resisted more than regulatorily.
RWE for post-approval BE.
2030+. Real-world evidence as confirmatory substrate. Technically feasible; politically contested; liability questions unresolved.
AI in bioequivalence.
Where AI is changing things now & 2026–2030AI is operational at the bioanalytical and pre-study end of BE; supportive at the modelling end (PBPK); and not yet acceptable as primary registration evidence. Inspection risk varies sharply by use case — site selection low, model-based biowaiver justification high.
Cohort enrichment & site selection.
Replaces manual site screening; augments volunteer-pool matching to inclusion criteria. Standard 2024+ via Medidata, ICON, Syneos platforms. Not yet explicitly covered in BE guidance. Inspection risk low — data selection, not data generation.
PBPK model qualification for biowaiver.
Augments BCS biowaiver justification with mechanistic evidence. FDA 2024 MIDD guidance permits as supportive; EMA cautious. Model qualification standards unspecified — the regulatory boundary is unclear. Risk high if a model fails post-approval.
Bioanalytical peak detection.
Replaces manual chromatogram review; augments operator variability reduction. Standard in LC-MS/MS instruments (Sciex, Waters, Thermo). Already under ICH M10 v2 scope discussion.
Pop-PK parameter estimation.
Augments BE analysis supporting long-acting injectables and population studies. Established via NONMEM, Monolix, Phoenix. ICH E9 statistical guidance framework, not BE-specific. No AI-specific friction.
RWE curation for synthetic controls.
Augments external control arm selection for synthetic BE studies. Pilot stage (FDA-led, EMA cautious). No formal BE-specific framework. Medium risk — data quality and representativeness contested.
AI formulation optimisation.
Augments excipient selection and release-mechanism design for modified-release. Research-stage; not yet operational in registration submissions. Considered a formulation development tool, not registration-quality. Low risk for 2026–2030.
Flow of a BE trial.
Operational pipeline · protocol → submissionThe lifecycle is short relative to a Phase 3 (typically 12–24 months from protocol to dossier) but unforgiving: every step must hold under regulator inspection years later.
Protocol design & statistical plan.
Study design selection (2×2 crossover, replicate, parallel), sample-size calculation under Schuirmann TOST, washout, fed/fasted scheme. SAP locked before unblinding. Choice anchors the entire submission.
Site qualification & regulator notification.
Phase I unit selection (volunteer recruitment capacity, bioanalytical proximity, inspection history). FDA IND-exempt or ANVISA notification, EU CTR submission via CTIS where applicable. Local ethics committee approval.
Bioanalytical method validation.
ICH M10 full validation: selectivity, accuracy & precision, calibration curve, matrix effect, stability, dilution integrity. Method must be production-ready before first sample.
Healthy volunteer enrolment.
Screening (PE, ECG, labs, drug-of-abuse). Informed consent. ANVISA volunteer registry check (Brazil). Replacement strategy defined if dropouts occur.
Dosing & sample collection.
Period 1 dosing, washout, Period 2 dosing (crossover) or replicate. Dense PK sampling around Cmax; tail sampling to support AUC0–t and lambda-z estimation. Chain of custody from cannula to freezer.
Bioanalytical sample analysis.
LC-MS/MS quantification under validated method. Run acceptance criteria (calibration, QC), incurred sample reanalysis (ISR) on ≥7% of samples. Out-of-trend investigation documented.
PK parameter derivation.
Non-compartmental analysis: Cmax (observed), AUC0–t (linear-up/log-down), AUC∞ (extrapolated), tmax, t½, lambda-z. Outlier handling per pre-specified rules. No post-hoc parameter substitution.
Statistical analysis.
Log-transformed ANOVA with sequence, period, subject(sequence), treatment terms. 90% CI of T/R geometric mean ratio for AUC and Cmax. RSABE scaling if HV (FDA) or Cmax-only widening (EMA/ANVISA). NTI tightening if applicable.
Clinical study report.
ICH E3-structured CSR. Bioanalytical report appendix (ICH M10 compliant). Statistical analysis appendix. Volunteer narratives for dropouts, adverse events, protocol deviations.
Module 5 compilation.
CTD Module 5.3.1 BE study reports. Cross-reference Module 3 (CMC, dissolution f2, formulation), Module 2.7 (clinical summary). Reference-product source documentation per jurisdiction.
Submission & regulator dialogue.
ANDA (FDA) / EMA generic / ANVISA generic / WHO PQ submission. Deficiency letters typically within 6–14 months. BE-specific questions: bioanalytical robustness, reference sourcing, statistical assumptions, NTI/HV designation.
Inspection readiness.
Pre-approval clinical and bioanalytical inspection (FDA BIMO, EMA national authority, ANVISA). Source documents, raw chromatograms, freezer logs, audit trail. The dossier is only as defensible as the binders behind it.
Use cases: what BE is actually for.
Why the domain existsBE is not one product; it is a regulatory shortcut applied across at least ten distinct programme types, each with its own statutory anchor and triggering event.
Generic approval · ANDA.
21 CFR 320 / Hatch-Waxman statutory requirement. BE demonstrates "same drug" therapeutically. Trigger: patent expiry, regulatory freedom to operate. Sponsor: generic manufacturer.
Generic approval international.
EMA Guideline 2010 Rev 1 / ANVISA RDC 742/2022. Trigger: product patent expiry in target market. Sponsor: generic manufacturer (local or multinational).
Brand formulation change.
FDA 21 CFR 320.24 / EMA CTD / ANVISA RDC. Post-approval variation: if manufacturing process or excipient changes materially, BE may be required. Trigger: scale-up, supply-chain disruption, cost optimisation.
Modified-release BE.
FDA/EMA guidance require fed-state BE for MR products; fasted BE alone insufficient. Sponsor: generic or innovator. Trigger: release-mechanism design.
Biosimilar comparability.
351(k) (FDA) / EMA biosimilar guideline / ANVISA RDC 55/2010. PK BE component of totality-of-evidence. Sponsor: Sandoz, Pfizer Biosimilars, Amgen Biosimilars, Samsung Bioepis. Trigger: biologic patent expiry, clinical advantage strategy.
Reference-scaling RSABE.
FDA 21 CFR 320 / EMA 2010 / ANVISA RDC 742. HV drugs (CV>30%) cannot meet 80–125% with standard power; widened bounds justify larger sample / longer duration. Trigger: preformulation evidence of high variability.
Narrow therapeutic index study.
FDA / EMA / ANVISA NTI lists trigger 90.00–111.11% bounds + full replicate design. Sponsor: generic (if drug on list); innovator (defending brand). Trigger: product on jurisdiction-specific NTI list.
Biowaiver justification.
ICH M9 BCS Class I / III criteria. Avoid in vivo BE study; cost / time savings. Sponsor: generic (primary incentive). Trigger: BCS classification + dissolution documentation sufficient.
Prequalification BE.
TRS 992 Annex 7 / ICH M9. Generics for HIV, malaria, TB, RH in LMIC markets. Trigger: global health procurement need (PEPFAR, Global Fund). Sponsor: LMIC generic manufacturer.
Paediatric formulation BE.
PREA / BPCA (FDA) / PIP (EMA). Some paediatric formulations require BE to adult reference. Trigger: paediatric mandate. Sponsor: innovator pharma responding to mandate.
Big players.
Sponsors · CROs · regulators · networksThe BE ecosystem is concentrated at both ends: a handful of CROs run most studies, a handful of regulators write most guidance, and the LMIC generic industry supplies the volume.
/ Generic pharma sponsors (India / LMIC volume)
Sun Pharma, Cipla, Aurobindo, Lupin, Torrent, Viatris (formerly Mylan), Pfizer (formerly Hospira), Teva Pharmaceutical. Role: ANDA, EMA-generic, WHO-PQ applicants. Volume-driven BE dossier builders.
/ Innovative pharma sponsors
Pfizer, Merck, AbbVie, Roche, Novartis, Eli Lilly. Role: BE for formulation changes, biosimilars, brand-generic alliances.
/ Biosimilar developers
Sandoz (Novartis), Pfizer Biosimilars, Amgen Biosimilars, Samsung Bioepis (Biogen / AstraZeneca), Teva Biosimilars. Role: comparability PK studies under 351(k) / EMA / ANVISA RDC 55/2010.
/ CROs · BE study conduct
Covance, Charles River, PAREXEL / Fortrea, PPD / Syneos, IQVIA, SNBL USA. Role: Phase I bioequivalence study design, conduct, bioanalytical oversight.
/ Bioanalytical labs
Worldwide Primates (Maryland), Absorption Systems, AAIPharma Services (Pennsylvania). Role: DBS / microsampling support, PK sample analysis, Phase I clinical-environment studies.
/ Regulators · BE-specific divisions
FDA / Office of Generic Drugs (OGD) — CDER division; product-specific guidances (PSGs); BE Helpline for sponsors. FDA / Office of Combination Products — PMOA determination for drug-device BE. EMA / CHMP / BE Working Group — with national competent authorities (BfArM, AIFA, ANSM, AEMPS). ANVISA / Gerência de Assuntos Científicos — RDC 742/2022, VICTOR portal, Rules 2024 implementation, healthy-volunteer registry oversight, MERCOSUR harmonisation. WHO Prequalification Programme (BE assessment team, established 2001) — TRS 992 Annex 7 implementation.
/ Academia · site networks
University of Maryland Center for Drug Development, University of Minnesota, Duke University. Role: academic partnerships, healthy-volunteer recruitment, methodology research.
Stakeholders.
Who is affected · who decides · who paysEach stakeholder has a distinct interest and a distinct lever. BE strategy fails when a sponsor optimises for one and ignores the others.
Selected writing on bioequivalence.
From the archiveWHO guidance on in vivo bioequivalence.
The WHO PQ-aligned framework for prequalified medicines. What LMIC supply-chain submissions actually require.
BA/BE trial flow.
End-to-end flow of a bioavailability/bioequivalence study: protocol → clinical → bioanalytical → statistics → submission.
Note for guidance on bioavailability and bioequivalence.
Reading the EMA guideline carefully — what's the BA half doing for the submission, what specific subsections regulators emphasise.
Biosimilars: transforming the future of healthcare.
The biosimilar pathway, the regulatory complexity, and the patient-access dimension. The next decade.
Overcoming challenges in clinical trials: a pathway to success.
Where BE study operations break down most often. Site selection, subject recruitment, sample handling, bioanalytical readiness.